Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery

F. Piérat, J.H. Wildhaber, I. Vrancken, S.G. Devadason, P.N. Le Souëf


ABSTRACT: Ionic detergents reduce electrostatic charge on plastic spacers, thereby improving in vitro drug delivery. The aim of this study was to gain practical information on the use of detergents and to evaluate the relevance of this information on in vivo drug deposition.

Measurement of electrostatic charge and salbutamol particle size distribution was carried out on detergent-coated and noncoated plastic spacers. The efficiency of four household detergents was compared, and the influence of dilution and the duration of the antistatic effect were studied. In addition, the level of radiolabelled salbutamol deposition in the lungs of eight healthy adults was compared after inhalation through a new versus a detergent-coated spacer.

In vitro, all tested detergents reduced the electrostatic charge on the spacer surface. This resulted in a mean increase of 37.4% (range 33.5–41.2) in small particle (<6.8 μm) salbutamol output compared with water-rinsed/drip-dried spacers. Dilution had no influence on the results and the effect lasted for at least four weeks. In vivo, the mean lung deposition of radiolabelled salbutamol in healthy subjects was 45.6% (range 43.4–49.5) through a detergent-coated spacer compared to 11.5% (range 7.6–17.9) through a static spacer (p<0.001).

In conclusion, household detergents offer a simple and practical solution to the problem of static on plastic spacers and significantly improve both in vitro and in vivo delivery of salbutamol.


The use of pressurized metered-dose inhalers (pMDIs) is associated with a number of problems, including high oropharyngeal deposition and co-ordination difficulties [1]. Holding chambers (spacers) have been designed to overcome these problems [2–5], and are widely used in aerosol therapy for both adults and children.

Due to the inherent nonconducting surface of plastic spacers, electrostatic charge inevitably accumulates on these devices and affects drug output [6–10]. In recent studies, it has been demonstrated that coating spacers with ionic detergent minimizes the static, and thereby improves in vitro drug delivery [8–10]. However, several questions remain. Are commercially-available detergents efficient and at what dilution? What is the duration of the antistatic effect? Is it affected by frequent handling of the spacer?

In addition, very little is known about the influence of electrostatic charge on in vivo drug deposition. There are few deposition studies involving the use of a plastic spacer, and the results are highly variable [11–14]. As the question of electrostatic charge affecting drug delivery from plastic spacers has not been adequately addressed prior to the work of O’CALLAGHAN and coworkers [6, 7], there is a strong possibility that a substantial part of the variability between studies using similar spacer devices and breathing patterns is due to differences in electrostatic charge. The effect of reducing electrostatic charge on the lung deposition from a spacer has not been adequately quantified.

The aims of this study therefore were to determine the antistatic efficiency of various household detergents in vitro, and to compare in vivo the deposition of radio-labelled salbutamol when delivered by a pMDI through either an electrostatically or a nonelectrostatically charged plastic spacer.

Materials and methods

Study design

In vitro studies. Measurements of electrostatic charge and delivery of salbutamol (Ventolin®; Allen & Hanbury’s, Sydney, NSW, Australia) were carried out on Volumatic® spacers (Allen & Hanbury’s), which were divided into two groups.

In the first group, non-detergent-coated spacers which were either: 1) new spacers, which had been stored in their original plastic bag; or 2) water-rinsed/drip-dried spacers (treatment recommended by the manufacturer).

In the second group, detergent-coated spacers were treated as shown in table 1. Different detergents were compared regarding their "antistatic property", and the following variables were studied: influence of dilution, duration of effect, and influence of handling.
The study was approved by the local hospital Ethics Committee.

Methods

Detergent coating. The spacers were soaked for a few minutes in the appropriate dilution of a detergent solution and allowed to drip-dry for 12–24 h. Four ionic detergents were tested in vitro (A: Cetrimide\(^{-}\), cationic, Ramprie Laboratories, Perth, WA, Australia; B: Farmland\(^{-}\), anionic, Coles Supermarkets, Melbourne, Victoria, Australia; C: Sunlight\(^{-}\), anionic, Lever Rexona, Sydney, NSW, Australia; D: Palmolive\(^{-}\), anionic, Colgate–Palmolive, Sydney, NSW, Australia). The spacers used for the in vivo study were coated with Palmolive (1:5,000 dilution).

Handling. Handling was performed by manually actuating salbutamol (2 puffs of 100 \(\mu\)g) twice a day in a group of coated spacers for the stated period of time. After each actuation, a continuous flow of 60 L-min\(^{-1}\) was applied for 5 s.

Measurement of electrostatic charge on spacers. Quantitative measurement of electrostatic charge on each spacer was performed using an electrometer (Model 37c; Electronic Instruments Ltd, Jacoby Mitchell, Sydney, NSW, Australia). Charge was measured along the inner surface of each spacer piece.

Surface charge density was classified into three categories: negligible (0–1.2 \(\mu\)C\(-\)cm\(^{-2}\)), low (1.2–3.3 \(\mu\)C\(-\)cm\(^{-2}\)) or high (3.3–6.7 \(\mu\)C\(-\)cm\(^{-2}\)).

Assessment of particle size distribution. Particle size distribution from salbutamol inhalers through the spacers was measured using a Multistage liquid impinger (MSLI; Copley, Nottingham, UK) with a continuous flow of 60 L-min\(^{-1}\). The pMDI was shaken for 30 s and two actuations were made prior to testing. Ten single actuations were introduced into the spacer, which was attached to the MSLI. The pMDI was shaken between actuations. Drug particles were deposited on the actuator, the spacer, the glass throat, or one of four stages according to their size. The particle size classifications for stages 1, 2, 3 and 4 were >13 \(\mu\)m, 6.8–13 \(\mu\)m, 3.1–6.8 \(\mu\)m and <3.1 \(\mu\)m, respectively. The actuator, spacer, glass throat and stages of the MSLI were washed with 45 mL methanol, and 5 mL 0.1 M NaOH was added to each wash. The absorbance (246 nm) of each sample was measured in duplicate using an ultraviolet spectrophotometer (Hitachi U-2000; Tokyo, Japan). The concentration of salbutamol was calculated using a standard curve obtained with known concentrations of salbutamol measured in 45 mL methanol and 5 mL 0.1 M NaOH. The standard curve was linear \((r^2=1.00)\) for concentrations between 0 and 20 \(\mu\)g\(\cdot\)mL\(^{-1}\). Each experiment was repeated four times for each different type of spacer.

Preparation of radiolabelled metered dose inhalers. Salbutamol (Ventolin\(^{-}\)) was labelled with \(^{99m}\)Te following the method of Köhler et al. [15], with some modifications. Technetium pertechnetate (\(^{99m}\)TeO\(_4^\text{2-}\); 500–600 MBq) was eluted from a radionuclide generator (Australian Radioisotopes, Lucas Heights, NSW, Australia) and added to 4 mL butanol in a separating funnel. After shaking vigorously, the two phases were allowed to separate. The top layer (organic phase) was collected, concentrated to dryness using a low flow of nitrogen (9–13 L\(\cdot\)min\(^{-1}\)). After all solvent had evaporated, the canister was placed on a hot plate for 30 min, at a temperature between 73 and 85\(^\circ\)C, and subsequently cooled in dry ice. The contents of a cooled commercial salbutamol pMDI were then poured into the radiolabel-containing canister, a metering valve was added, and the canister was immediately sealed by a crimper (type 555 G, Pamasol; Willi

### Table 1. – Treatment of detergent coated spacers for in vitro study

<table>
<thead>
<tr>
<th>Variable to be tested</th>
<th>Detergent</th>
<th>Dilution</th>
<th>Time between coating and testing</th>
<th>Handling</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choice of detergent/ influence of dilution</td>
<td>A: 1:125</td>
<td>12–24 h</td>
<td>Without handling</td>
<td></td>
</tr>
<tr>
<td>D: 1:5000</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>B: 1:125</td>
<td>12–24 h</td>
<td>handling</td>
<td></td>
</tr>
<tr>
<td>C: 1:2500</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D: 1:5000</td>
<td>1:7500</td>
<td>1:10000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of effect/ influence of handling</td>
<td>D: 1:5000</td>
<td>Week 0 (24 h)</td>
<td>Without handling</td>
<td></td>
</tr>
<tr>
<td>A: Week 1 and with handling</td>
<td>B: Week 2</td>
<td>handling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C: Week 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D: Week 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Detergents used were: A: Cetrimide; B: Farmland; C: Sunlight; D: Palmolive.

All experiments were carried out in controlled laboratory conditions. The mean temperature was 23\(^\circ\)C (range 22–24) and the mean relative humidity was 62\% (range 56–70).

In vivo study. Eight healthy nonsmoking volunteers (five males) aged between 25 and 42 yrs were recruited. All participants gave written informed consent. They had normal predicted values for forced vital capacity (FVC) (mean 103.2\%, range 85–112) and forced expiratory volume in one second (FEV\(_1\)) (mean 100.5\%, range 87–111). The study was approved by the local hospital Ethics Committee.

All subjects attended the department on two occasions, at least 48 h apart. On each visit, in random order, they were asked to inhale a 500 \(\mu\)g dose (5 \times 100 \(\mu\)g) of technetium-99m-labelled salbutamol through either a high electrostatic (new) or a low electrostatic (detergent-coated) Volumatic spacer. Prior to testing, they were instructed on the use of the pMDI and the spacer, and were trained using a Vitalograph Compact Spirometer (Vitalograph Ltd, Buckingham, UK) to produce a slow inhalation with a flow of 20–25 L\(\cdot\)min\(^{-1}\). The inhaler was first shaken for 30 s and primed before use. The subjects were asked to exhale and, after actuation of the pMDI through the spacer, they performed a slow maximal inhalation. They held their breath for 10 s and then expired through a filter (Curity\(^{-}\), Anesthesia Filter, Kendall, MA, USA). The inhaler was shaken between each actuation. For each subject, it took 90–120 s to inhale the five actuations. Drug particles were deposited on the actuator, the spacer, the glass throat, or one of four stages attached to the MSLI. The pMDI was shaken for 30 s and two actuations were made prior to testing. Ten single actuations were introduced into the spacer, which was attached to the MSLI. The pMDI was shaken between actuations. Drug particles were deposited on the actuator, the spacer, the glass throat, or one of four stages according to their size. The particle size classifications for stages 1, 2, 3 and 4 were >13 \(\mu\)m, 6.8–13 \(\mu\)m, 3.1–6.8 \(\mu\)m and <3.1 \(\mu\)m, respectively. The actuator, spacer, glass throat and stages of the MSLI were washed with 45 mL methanol, and 5 mL 0.1 M NaOH was added to each wash. The absorbance (246 nm) of each sample was measured in duplicate using an ultraviolet spectrophotometer (Hitachi U-2000; Tokyo, Japan). The concentration of salbutamol was calculated using a standard curve obtained with known concentrations of salbutamol measured in 45 mL methanol and 5 mL 0.1 M NaOH. The standard curve was linear \((r^2=1.00)\) for concentrations between 0 and 20 \(\mu\)g\(\cdot\)mL\(^{-1}\). Each experiment was repeated four times for each different type of spacer.

Preparation of radiolabelled metered dose inhalers. Salbutamol (Ventolin\(^{-}\)) was labelled with \(^{99m}\)Te following the method of Köhler et al. [15], with some modifications. Technetium pertechnetate (\(^{99m}\)TeO\(_4^\text{2-}\); 500–600 MBq) was eluted from a radionuclide generator (Australian Radioisotopes, Lucas Heights, NSW, Australia) and added to 4 mL butanol in a separating funnel. After shaking vigorously, the two phases were allowed to separate. The top layer (organic phase) was collected, concentrated to dryness using a low flow of nitrogen (9–13 L\(\cdot\)min\(^{-1}\)). After all solvent had evaporated, the canister was placed on a hot plate for 30 min, at a temperature between 73 and 85\(^\circ\)C, and subsequently cooled in dry ice. The contents of a cooled commercial salbutamol pMDI were then poured into the radiolabel-containing canister, a metering valve was added, and the canister was immediately sealed by a crimper (type 555 G, Pamasol; Willi
Mäder, Pfäffikon Switzerland). The canister was placed on a shaker for 30 min, and was then ready for testing.

The exact dose of activity per actuation was determined by placing the labelled canister in an ionization chamber (Atomlab 200 dose calibrator; Gammanetics, Sydney, NSW, Australia) both before and after actuation of five puffs.

Validation of radiolabelling technique. Accuracy of labelling was confirmed using a MSLI to ensure that the label followed the drug and that the radiolabelling method did not significantly alter the particle size distribution of the aerosol generated by the salbutamol pMDI. The particle size distribution of commercial salbutamol pMDIs was compared to that of both drug and radiolabel from the labelled inhalers. For the labelled pMDIs, the distribution of radioactivity in the different washes (actuator, glass throat, stages 1–4) was measured in an ionization chamber (Atomlab 200 dose calibrator). On the study days, the particle size distribution from the labelled inhaler was assessed prior to administration to confirm that the labelling was satisfactory. These measurements were repeated after the studies to make sure that no change had occurred.

Lung function tests. As normal lung function was an inclusion criterion, FVC and FEV1 were measured in all participants, using a PneumoCheck Spirometer (61000; Welch Allyn, Skaneateles Falls, NY, USA).

Imaging procedures. A flood source containing approximately 37 MBq 99mTc was used to obtain individual studies approximately 37 MBq 99mTc was used to obtain individual.

Fig. 1. – Small particle (<6.8 μm) output of salbutamol pressurized metered-dose inhalers through new and water-rinsed/drip-dried spacers compared to that through spacers coated with different detergents (A: Cetrinide®; B: Farmland®; C: Sunlight®; D: Palmolive®) using six different dilutions (□ :1/125; ○ :1/250; ◊ :1/5,000; ■ :1/ 7,500; and □ :1/10,000). Values are presented as mean±sd.

Using coated spacers, the mean (sd) small particle (<6.8 μm) salbutamol output ranged from 50.1% (4.0) using detergent A to 53.1% (3.1) using detergent D. There was no significant difference between the four detergents tested. This mean output was significantly greater in comparison with that from the new spacers (36.2% (3.5); p<0.001), and the water-rinsed/drip-dried spacers (37.6% (5.1); p<0.002) (fig. 1).

All dilutions gave similar results, regardless of the detergent used. Even using a spacer coated with very dilute detergent (1:10,000), the small particle output of salbutamol was significantly higher than that from a water-rinsed/ drip-dried spacer (p<0.05 for detergent A; p<0.005 for detergents B, C and D) (fig. 1).

Analysis. Statistical analysis was carried out using version 5a of the Microsoft Excel Analysis ToolPak (Microsoft Corporation, Redwood, WA, USA), using analysis of variance (ANOVA) for repeated measurements. A p-value <0.05 was considered significant.

Results

In vitro studies

Electrostatic charge was negligible (<1.2 μC·m−2) on the surface of all detergent-coated spacers, regardless of the brand of detergent or the dilution used, and high (>5 μC·m−2) on all noncoated spacers.

Fig. 2. – Particle size distribution of drug from commercial and labelled salbutamol pressurized metered-dose inhalers (pMDIs) and radiolabel distribution from labelled salbutamol pMDIs. (Multistage liquid impinger with a continuous flow of 60 L·min−1). Values are presented as mean and so. □ : Unlabelled drug; © : labelled drug; ® : radiolabel.
With or without handling, electrostatic charge became detectable 1 week after coating but remained in the low range (1.2–3.3 μC·m⁻²) for at least 4 weeks. However, the small particle output of salbutamol did not significantly change: without handling, the mean (SD) output was 51.2% (0.6) at week 0 and 47.9% (4.7) at week 4; with handling, the mean (SD) output was 47.9% (5.3) at week 0 and 46.6% (6.3) 4 weeks after coating.

In vivo study

The particle size distribution of salbutamol pMDIs was compared to the distribution of both drug and radiolabel from the labelled inhalers as part of the method validation (fig. 2). There was a good correlation between label and drug delivery, particularly for stages 3 and 4: the mean output of particles <6.8 mm, expressed as a percentage of the metered dose, was 46.7, 46.2 and 47.7% for unlabelled drug, labelled drug and radiolabel, respectively. The radiolabelled doses were reproducible. With a separate canister on each of four study days a 1.9–2.1 MBq (mean 2.0 MBq) dose and a 520–570 mg salbutamol dose (mean 545 mg) per five actuations were obtained.

Electrostatic charge was high (>5 μC·m⁻²) on the surface of all new spacers and negligible (<1.2 μC·m⁻²) on all detergent-coated spacers. Comparison of lung deposition of salbutamol after inhalation through an electrostatic and non-electrostatically charged spacer is shown for each subject in figure 3.

Figure 4 summarizes the deposition, expressed as a percentage of total actuated dose, in the actuator, spacer, gastrointestinal tract (mouth, throat, oesophagus, stomach, mouth washing, gargle washing), lungs and expiratory filter. There was a three-fold increase in lung deposition from detergent-coated spacers (mean 45.6% (2.2); range 43.4–49.5) compared to static spacers (mean 11.5% (3.5); range 7.6–17.9). The mean (range) gastro-intestinal deposition was 2.4% (1.0–3.9) through a static spacer and 8.8% (4.1–11.2) through a nonstatic spacer (p<0.001). The mean (range) amount of salbutamol remaining in the static spacers was 76.7% (71.8–81.4) compared to 33.1% (26.0–40.8) in the detergent-coated spacers (p<0.001). Typical deposition patterns are shown in figure 5.

Discussion

The present study demonstrated that reducing the electrostatic charge on a plastic spacer significantly improved both in vitro and in vivo drug delivery. The magnitude of the in vivo increase was remarkably high.

The in vitro studies confirm and extend the authors’ previous work [8, 10]. Coating a plastic spacer with an ionic detergent is a simple method of reducing electrostatic charge, thereby increasing the in vitro drug delivery. The four detergents tested gave similar results: a mean increase of 37.4% in the output of small particles (<6.8 μm) when using coated spacers compared to water-rinsed/drip-dried spacers. Most commercially-available dishwashing liquids

![Fig. 3.](image-url) Comparison of salbutamol lung deposition, expressed as percentage of total actuated dose, after inhalation of salbutamol through electrostatically charged (new; †) and non-electrostatically charged (detergent-coated; □) Volumatic spacers in eight healthy adults.

![Fig. 4.](image-url) Relative deposition of salbutamol, expressed as a percentage of total actuated dose, in the actuator, spacer, gastrointestinal tract (mouth, throat, oesophagus and stomach (G)); lungs (L) and expiratory filter (EF), after inhalation through electrostatically charged (new; †) and non-electrostatically charged (detergent-coated; □) Volumatic spacers in eight healthy adults. Values are presented as mean and so.

![Fig. 5.](image-url) Typical deposition patterns of radioaerosol in the same subject after inhalation through a new and a detergent-coated spacer (posteroanterior view).
are made up of ionic (mainly anionic) detergents. Therefore, the present study would suggest that similar results may be obtained for most household detergents. All dilutions of the detergents were equally effective. The antistatic effect lasted for at least four weeks, even with repeated handling of the spacer.

The in vivo study demonstrates that electrostatic charge plays an important role in the lung deposition of salbutamol through plastic spacers, and that the effect of reducing charge is much greater than expected. Using detergent-coated Volumatic spacers, a mean lung deposition of salbutamol of 45.6% was found, which was much higher than in previous studies [11–14, 18, 19].

Most deposition studies using radiolabelled salbutamol have examined the use of pMDIs, dry powder inhalers, or nebulizers, and have reported mean lung deposition percentages between 9 and 21.6% [11, 18, 19]. There are few deposition studies involving the use of a spacer device, and the results of these studies are highly variable. Tal et al. [12] evaluated the deposition of directly radiolabelled salbutamol in two adult volunteers after inhalation through an Aerochamber [13], and found a mean lung deposition of 19%. However, their study refers to deposition in children rather than in adults, and the deposition values in that study were 19%. Nevertheless, their study demonstrates that electrostatic charge plays a major role. A low-volume metal spacer [21] has been developed to eliminate the problem of static charge, but in view of the present results and the issues of cost and availability, a simple plastic spacer may remain the device of choice worldwide.

The authors’ studies were performed using chlorofluorocarbon (CFC)–salbutamol, but previous studies have demonstrated that the electrostatic charge affects the delivery of other drugs from plastic spacers, such as sodium cromoglycate [6] and budesonide [7]. Further studies with hydroxyfluoroalkane (HFA) formulations are needed.

In conclusion, the coating of plastic spacers with household detergents significantly improves both in vitro and in vivo salbutamol delivery. The present in vitro studies suggest that most commercially-available detergents may do this efficiently, even at low concentrations, and that the antistatic property of detergent coating lasts for at least 4 weeks. The present in vivo study confirms that detergents offer a practical solution to the problem of electrostatic charge on plastic spacers and improve lung deposition of salbutamol much more than expected. The variability of deposition is also reduced. In addition, these studies allow us to provide practical advice on the care of all plastic spacers. It is recommended that plastic spacers should be soaked in a dilute solution of household detergent and then allowed to drip-dry without water-rinsing. This treatment should be repeated at least once a month.

Further studies are needed to extend the scope of these findings to the use of inhaled corticosteroids in asthmatic patients and to assess the clinical relevance of this information. However, the present results indicate that detergent-coating of plastic spacers is a simple way of providing a greater and more predictable delivery of drug to the airways, and thus may indicate the potential for dose reduction of inhaled medications.

Acknowledgements. We are indebted to R. Troedson, (Nuclear Medicine Department), and C. Roller, J.M. Wilson, T. Lagana and B.C. Thompson for their technical assistance.

References


